Filing Flows › Celldex Therapeutics (CLDX) › Stock forecast & fair value
Celldex Therapeutics (CLDX) stock forecast and price target
Celldex Therapeutics (CLDX) trades at $29.87. 14 analysts' median price target is $64.00 (+114%), from $29.00 to $100.00.
Celldex Therapeutics' latest quarter
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CLDX stock?
The median of 14 analysts' 12-month targets is $64.00, +114% from $29.87; the range is $29.00 to $100.00. The average rating is strong buy.
Does Celldex Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is CLDX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.